We are live on ! Find out more
VanEck Associates

VanEck Associates Portfolio holdings

AUM $133B
1-Year Est. Return 72.99%
This Fund
S&P 500
This Quarter Est. Return
+0.13%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$19.8B
AUM Growth
+$155M
Cap. Flow
+$505M
Cap. Flow %
2.55%
Top 10 Hldgs %
28.01%
Holding
708
New
61
Increased
262
Reduced
353
Closed
27

Top Buys

Rank Stock Value
1
B
Barrick Mining
B
+$230M
2
PSX icon
Phillips 66
PSX
+$157M
3
CNH
CNH Industrial
CNH
+$139M
4
GG
Goldcorp Inc
GG
+$116M
5
CNX icon
CNX Resources
CNX
+$113M

Sector Composition

Rank Sector Weight
1 Materials 42.53%
2 Energy 27.86%
3 Healthcare 5.32%
4 Industrials 5.18%
5 Consumer Staples 3.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JNJ icon
126
Johnson & Johnson
JNJ
$618B
$24.1M 0.12%
263,187
+6,147
+2% +$567K
ANDE icon
127
Andersons Inc
ANDE
$2.41B
$24.1M 0.12%
404,885
-20,740
-5% -$1.1M
DRC
128
DELISTED
DRESSER-RAND GROUP INC
DRC
$23.9M 0.12%
401,639
-18,730
-4% -$1.11M
VRTX icon
129
Vertex Pharmaceuticals
VRTX
$121B
$23.3M 0.12%
313,353
+70,918
+29% +$4.94M
RDC
130
DELISTED
Rowan Companies Plc
RDC
$23.1M 0.12%
654,014
-30,670
-4% -$1.1M
ILMN icon
131
Illumina
ILMN
$31B
$22.5M 0.11%
208,963
-28,027
-12% -$2.57M
INCY icon
132
Incyte
INCY
$24.2B
$21.5M 0.11%
424,146
+61,211
+17% +$2.66M
TXN icon
133
Texas Instruments
TXN
$252B
$21.3M 0.11%
484,227
+15,219
+3% +$637K
ANV
134
DELISTED
Allied Nevada Gold Corp
ANV
$20.7M 0.1%
5,823,070
-124,226
-2% -$466K
REGN icon
135
Regeneron Pharmaceuticals
REGN
$78.5B
$20.6M 0.1%
74,722
-2,931
-4% -$843K
NVS icon
136
Novartis
NVS
$297B
$20.3M 0.1%
281,720
+6,252
+2% +$435K
IWM icon
137
iShares Russell 2000 ETF
IWM
$79.8B
$19.9M 0.1%
172,535
-189,017
-52% -$20.9M
VALE icon
138
Vale
VALE
$64.1B
$19.9M 0.1%
1,303,230
+284,467
+28% +$4.42M
RIO icon
139
Rio Tinto
RIO
$158B
$19.5M 0.1%
345,542
+26,980
+8% +$1.4M
PTEN icon
140
Patterson-UTI
PTEN
$3.98B
$19.2M 0.1%
760,088
-52,273
-6% -$1.25M
PFE icon
141
Pfizer
PFE
$143B
$18.5M 0.09%
637,209
+755
+0.1% +$22K
VEON icon
142
VEON
VEON
$3.62B
$16.9M 0.09%
52,196
-10,395
-17% -$3.32M
ANR
143
DELISTED
Alpha Natural Resources Inc
ANR
$16.7M 0.08%
2,335,007
+6,216
+0.3% +$42K
TLK icon
144
Telkom Indonesia
TLK
$14.5B
$15.5M 0.08%
863,736
-16,154
-2% -$305K
TDW icon
145
Tidewater
TDW
$3.73B
$15.5M 0.08%
8,091
-374
-4% -$711K
LNN icon
146
Lindsay Corp
LNN
$1.13B
$15.4M 0.08%
185,883
-9,364
-5% -$729K
QGENF
147
DELISTED
QIAGEN NV
QGENF
$15.3M 0.08%
644,488
+88,829
+16% +$2.11M
UTHR icon
148
United Therapeutics
UTHR
$25.8B
$15.3M 0.08%
135,054
+16,676
+14% +$1.5M
BMRN icon
149
BioMarin Pharmaceuticals
BMRN
$11.6B
$15.1M 0.08%
214,139
-56,701
-21% -$3.85M
WOLF icon
150
Wolfspeed
WOLF
$1.23B
$15M 0.08%
239,914
-2,229
-0.9% -$138K

Similar funds

VanEck Associates's Q4 2013 Portfolio in Review

As of Q4 2013, VanEck Associates held 708 positions worth $19.8B, up 0.79% from $19.6B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

VanEck Associates's Q4 2013 filing shows 61 new, 262 increased, 353 reduced and 27 closed positions. Its largest new stake was CNH Industrial: 13,883,315 shares worth $137M. The largest sale was Pioneer Natural Resource Co., an estimated $131M.

By sector, the portfolio is most concentrated in Materials at 43% of assets, down from 45% a quarter earlier, followed by Energy and Healthcare.

  • VanEck Associates's largest Q4 2013 buy was CNH Industrial: 13,883,315 shares worth $137M.
  • VanEck Associates added most to Barrick Mining in Q4 2013, an estimated $230M increase.
  • VanEck Associates's biggest Q4 2013 reduction was Pioneer Natural Resource Co., cutting an estimated $131M.
  • VanEck Associates fully exited iShares S&P 500 Value ETF in Q4 2013, selling an estimated $27.2M.
  • VanEck Associates's ten largest holdings make up 28% of its $19.8B portfolio in Q4 2013.
  • VanEck Associates opened 61 new positions and closed 27 in Q4 2013.
  • VanEck Associates's portfolio value rose 0.79% quarter-over-quarter to $19.8B.

Based on VanEck Associates's 13F filing for Q4 2013, filed 12 Feb 2014.